

## Special Issue

# APAA: Asthma Pharmacogenetics across Ages

### Message from the Guest Editors

Pharmacogenetics has had substantial impact in the treatment of some diseases, but despite much progress on the genetics of asthma, heterogeneity of asthma across the age spectrum has hindered translation. This Special Issue will focus on age-dependent factors likely to yield important indicators of asthma drug response that are applicable to children and adults. A specific interest is genetic and genomic mechanisms regulating response to asthma treatments including inhaled steroids and beta2-agonists and the differences across the age spectrum. Using age-dependent biomarkers to predict asthma drug response carries tremendous promise to improve asthma management by allowing clinicians to tailor asthma management to individual needs. Emerging results point to less asthma suffering and substantial cost-savings as the number of exacerbations from asthma will decrease. This Special Issue of JPM: APAA will focus on all aspects of pharmacogenetics of asthma; the heterogeneity of asthma subtypes related to age; age-based genetic, metabolomic, transcriptomic, and other broad-based investigations of asthma pharmacology. We welcome all submissions related to these topics.

---

### Guest Editors

Prof. Ann Chen Wu

Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215-5301, USA


Dr. Michael McGeachie

Channing Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02215, USA

---

### Deadline for manuscript submissions

closed (5 April 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/46887](https://mdpi.com/si/46887)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).